WO2008112695A3 - Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment - Google Patents

Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment Download PDF

Info

Publication number
WO2008112695A3
WO2008112695A3 PCT/US2008/056523 US2008056523W WO2008112695A3 WO 2008112695 A3 WO2008112695 A3 WO 2008112695A3 US 2008056523 W US2008056523 W US 2008056523W WO 2008112695 A3 WO2008112695 A3 WO 2008112695A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
protein kinase
kinase inhibitors
indacenes
tetraaza
Prior art date
Application number
PCT/US2008/056523
Other languages
French (fr)
Other versions
WO2008112695A2 (en
Inventor
Pingda Ren
Xia Wang
Yun He
Barun Okram
Xiaodong Wang
Guobao Zhang
Zuosheng Liu
Yi Liu
Pamela A Albaugh
Original Assignee
Irm Llc
Pingda Ren
Xia Wang
Yun He
Barun Okram
Xiaodong Wang
Guobao Zhang
Zuosheng Liu
Yi Liu
Pamela A Albaugh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Pingda Ren, Xia Wang, Yun He, Barun Okram, Xiaodong Wang, Guobao Zhang, Zuosheng Liu, Yi Liu, Pamela A Albaugh filed Critical Irm Llc
Publication of WO2008112695A2 publication Critical patent/WO2008112695A2/en
Publication of WO2008112695A3 publication Critical patent/WO2008112695A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of Alk, Abl, Aurora-A, B-raf, Bcr-Abl, BRK, Blk, Bmx, cKit, c-RAF, cSRC, CSK, FLT1, Fms, Fyn, JAK2, KDR, Lck, Lyn, PDGFRα, PDGFRβ, PKCα, p38 (p38 MAP kinase, SAPK2α), Src, SIK, Syk, Tie2 and TrkB kinases. Formula (I) wherein L is attached at any position on Ring E and is -NR4(CO)CR2)n or - (CO)NR4(CR2)ni X is a bond or C(O); Y is a 5-7 membered carbocyclic ring, aryl, heterocyclic ring or heteroaryl;
PCT/US2008/056523 2007-03-12 2008-03-11 Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment WO2008112695A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89442007P 2007-03-12 2007-03-12
US60/894,420 2007-03-12

Publications (2)

Publication Number Publication Date
WO2008112695A2 WO2008112695A2 (en) 2008-09-18
WO2008112695A3 true WO2008112695A3 (en) 2008-12-18

Family

ID=39758477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/056523 WO2008112695A2 (en) 2007-03-12 2008-03-11 Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment

Country Status (1)

Country Link
WO (1) WO2008112695A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072657A1 (en) 2008-02-29 2010-09-15 Genentech Inc RAF INHIBITING COMPOUNDS AND METHODS FOR USE
PE20091561A1 (en) 2008-02-29 2009-10-30 Array Biopharma Inc RAF INHIBITING COMPOUNDS AND METHODS FOR THEIR USE
RS54560B1 (en) * 2008-06-10 2016-06-30 Abbvie Inc. Tricyclic compounds
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
WO2011068899A1 (en) 2009-12-01 2011-06-09 Abbott Laboratories Novel tricyclic compounds
CN104370909B (en) 2009-12-01 2018-09-11 Abbvie 公司 Tricyclic compound
MX2014013373A (en) 2012-05-15 2015-08-14 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1.
WO2013171642A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CA2868958C (en) 2012-05-15 2020-09-01 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
JP6080947B2 (en) 2012-05-15 2017-02-15 ノバルティス アーゲー Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
WO2014100620A2 (en) * 2012-12-21 2014-06-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2015031562A1 (en) * 2013-08-29 2015-03-05 Bristol-Myers Squibb Company PROCESS FOR THE PREPARATION OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1H-PYRAZOL-3-YLAMINO)-6-ETHYL-1-METHYL-1,6-DIHYDROIMIDAZO[4,5-d]PYRROLO[2,3-b]PYRIDINE-7-CARBOXAMIDE
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
AU2016340167B2 (en) 2015-10-16 2021-06-24 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2018208132A1 (en) * 2017-05-12 2018-11-15 Korea Research Institute Of Chemical Technology Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient
KR102128018B1 (en) 2017-05-12 2020-06-30 한국화학연구원 pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient
BR112020022442A2 (en) * 2018-05-02 2021-02-09 Jw Pharmaceutical Corporation new heterocyclic derivative
KR102129114B1 (en) * 2018-07-26 2020-07-02 주식회사 온코파마텍 A compound having TrkA inhibitory activity, and a pharmaceutical composition for preventing or treating pain containing the compound as an active ingredient
BR112021007435A2 (en) 2018-10-25 2021-08-03 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
US20210361669A1 (en) 2018-10-25 2021-11-25 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
AU2020307293A1 (en) * 2019-06-25 2022-01-27 Sinopsee Therapeutics Compounds for treatment of cancer
TW202313053A (en) * 2021-07-30 2023-04-01 瑞士商艾克泰聯製藥有限公司 Pyrazolopyrimidines and their uses as pdgfr inhibitors
WO2024104968A1 (en) * 2022-11-14 2024-05-23 Actelion Pharmaceuticals Ltd Pyrazolopyrrolopyridazines and their uses as pdgfr inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085248A1 (en) * 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
WO2007024680A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085248A1 (en) * 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
WO2007024680A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P. TRAXLER, G. BOLD, J. FREI, M. LANG, N. LYDON, H. METT, E. BUCHDUNGER, T. MEYER, M. MÜLLER, P. FURET: "Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, 1997, pages 3601-3616, XP002497479 *

Also Published As

Publication number Publication date
WO2008112695A2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2008112695A3 (en) Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
MX2009013782A (en) Protein kinase inhibitors and methods for using thereof.
MX2010002005A (en) 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors.
MX2009010728A (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors.
ATE499374T1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
MX2008002165A (en) Compounds and compositions as protein kinase inhibitors.
MX2009013781A (en) Protein kinase inhibitors and methods for using thereof.
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents
NO20063758L (en) Pyrazolo [1,5-A] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
PL1896470T3 (en) Pyrrolopyridine derivatives as protein kinase inhibitors
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
TW200602328A (en) Quinazoline derivatives
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
WO2006081172A3 (en) Compounds and compositions as protein kinase inhibitors
WO2008046003A3 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
EP2526933A3 (en) Inhibitors of bruton's tyrosine kinase
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
MX2009003456A (en) Compounds and compositions as protein kinase inhibitors.
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
MX2010002004A (en) 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors.
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
PT1940844E (en) Compounds and compositions as protein kinase inhibitors
WO2006105442A3 (en) Spirocyclic heterocyclic derivatives and methods of their use
TW200628466A (en) Quinazoline derivatives

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731903

Country of ref document: EP

Kind code of ref document: A2